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 CURRENTOPINION Practical multimodal care for cancer cachexia
Matthew Maddocksa, Jane Hopkinsonb, John Conibearc, Annie Reevesc,
Clare Shawd, and Ken C.H. Fearone
Purpose of review
Cancer cachexia is common and reduces function, treatment tolerability and quality of life. Given its
multifaceted pathophysiology a multimodal approach to cachexia management is advocated for, but can
be difficult to realise in practice. We use a case-based approach to highlight practical approaches to the
multimodal management of cachexia for patients across the cancer trajectory.
Recent findings
Four cases with lung cancer spanning surgical resection, radical chemoradiotherapy, palliative
chemotherapy and no anticancer treatment are presented. We propose multimodal care approaches that
incorporate nutritional support, exercise, and anti-inflammatory agents, on a background of personalized
oncology care and family-centred education. Collectively, the cases reveal that multimodal care is part of
everyone’s remit, often focuses on supported self-management, and demands buy-in from the patient and
their family. Once operationalized, multimodal care approaches can be tested pragmatically, including
alongside emerging pharmacological cachexia treatments.
Summary
We demonstrate that multimodal care for cancer cachexia can be achieved using simple treatments and
without a dedicated team of specialists. The sharing of advice between health professionals can help
build collective confidence and expertise, moving towards a position in which every team member feels
they can contribute towards multimodal care.
Keywords
cancer cachexia, clinical education, multimodal care, supportive care
INTRODUCTION
Cancer cachexia is a ‘multifactorial syndromecharac-
terized by an ongoing loss of skeletal muscle mass,
withorwithout a loss of fatmass, that cannot be fully
reversed by conventional nutritional support and
leads to progressive functional impairment’ [1]. It
is common,especially amongpatientswithadvanced
solid cancers [1,2], and impacts adverselyon function
[3,4], treatment tolerability [5], health service use [6],
quality of life [7], and survival [8]. The pathophysi-
ology of cancer cachexia is complex but can be
characterized by a negative protein and energy bal-
ance, driven by a variable combination of reduced
food intake and abnormal metabolism [9]. Persistent
inflammatory and stress responses, coupled with
tumour-derived factors, led to reduced food intake
[9], increased resting energy expenditure [10], and
net loss of lean tissue [11,12]. The degree of cachexia
and the predominant phenotype depends on
the tumour and patient characteristics [1,8,13],
which can be uncovered with a comprehensive
standardized assessment [14].
Given the multifaceted pathophysiology and
heterogeneous presentation of cancer cachexia
[15], a multimodal approach to its management
has been proposed [16] and advocated for by
experts in the field [9,11,14,17–20]. Core treatment
goals of the approach include ensuring sufficient
energy and protein intake, maintaining physical
activity and muscle mass, and reducing systemic
inflammation where present [14]. Core component
interventions would therefore include nutritional
support, physical activity and exercise, and
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anti-inflammatory agents, for example, n-3 fatty
acids or NSAIDs. These should be offered on a back-
ground of personalized oncological and nursing
management, and family-centred education [21].
A multimodal approach has a strong theoretical
backing but can be difficult to realise in clinical
practice [22]. With only a handful of specialized
cachexia clinics and limited allied health
professionals (AHPs), responsibility falls to those
providing routine care, usually the oncologist
and/or cancer nurse [23
&
]. There are time and
resource restraints, few guidelines providing recom-
mendations for cachexia management, and there
can be the perception that cachexia management
demands specialist expertise [23
&
]. In this article, we
use a case-based approach to highlight practical
approaches to the multimodal management of
cachexia for patients across the cancer trajectory.
The cases are based on patients attending a lung
clinic in a tertiary cancer centre. The suggested
treatments are informed and guided by recent
evidence, but have been selected with the generalist
in mind and do not require specialist equipment
and expertise. The intention is to demonstrate that
multimodal care can be implemented into routine
clinical practice.
CASE #1: LISTED FOR SURGICAL
RESECTION
John, aged 75, has been listed for surgical resection
of a T1aNoMo adenocarcinoma of the lung (Fig. 1).
His current WHO performance status is 1. He has
concurrent COPD, suffers from severe anxiety, and
continues to smoke half-an-ounce of rolling tobacco
daily. He reports losing about half a stone and his
current BMI is 17.8 kg/m2, CRP is 119mg/L, and
appetite is lower than usual. Depending on Johns’
pathological staging, he may need further adjuvant
chemotherapy. His oncologist has prescribed post-
operative pabrinex and vitamin B12 and is support-
ing John to stop smoking.
John’s BMI is below normal and he is severely
malnourishedwhich could impact negatively on the
outcome of his surgery in terms of complications
and length of stay. His weight loss and associated
problems should be acknowledged [24], with an
explanation that surgery can cure lung cancer
and, with adequate nutrition, the weight can
be regained. A nutritional care plan over the next
7–10 days could include dietary intake and oral
nutritional supplements or alternatively enteral
tube feeding [25]. The latter is not often offered to
patients but may be useful given John’s anxiety if he
is unable to meet his nutritional requirements
orally. Food fortification advice would include
information about the use of high energy and high
protein foods, for example, the use of full cream
milk, additional cheese or cream in soup or mashed
potato, the use of flavoured oils (olive, nut or veg-
etable) on foods such as soup, rice or pasta. Use of
high energy fluids can add to his energy intake, for
example milky coffee, hot chocolate, malted milk
drinks, milkshakes or fruit smoothies. High energy
snacks between meals are also useful to increase
energy intake including nuts, dried fruit, cheese
or nut butter on crackers or toast, cake and biscuits,
KEY POINTS
 A multimodal approach to cancer cachexia
management has a strong theoretical rationale, but can
be difficult to realise in practice with time and resource
restraints, limited guidelines, and the perception that
cachexia management requires a specialist team.
 Multimodal care can include nutritional, exercise based,
anti-inflammatory and educational components, offered
on a background of personalized oncology and nursing
practice.
 Tailored multimodal care can be delivered without a
specialist team, and starts with simple advice and
education, treatment of nutritional impact symptoms
(e.g. sore mouth, constipation, and pain), and
promoting good health behaviours (e.g. eating well,
staying physically active).
 Once operationalized, multimodal care approaches for
cancer cachexia can be tested pragmatically, including
alongside emerging pharmacological treatments.
John:
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surgical
resection
Support
smoking
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weight loss as
part of cancer
condition
Inform
patient about
high protein,
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operative
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Use recovery
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physical
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Consult
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nutritional
supplements
or enteral
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FIGURE 1. John, listed for surgical resection.
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but dietary counselling must discuss the foods that
the patient would be able to eat in addition to usual
meals. Talking with and his wife together can facili-
tate dialogue about sensitive topics, conflicts, and
strengths they have developed to manage his COPD
that might be helpful now [26
&
]. Oral nutritional
supplements may improve overall dietary intake in
some patients [27]. Adherence to taking these may
be improved with the added expertise of a dietician
to discuss taste preference, formats of supplements
available and suitable usage in addition to food
[28–31]. When introducing them talking about
ways other couples have coped in similar situations
could be used as an indirect way of normalizing
experience, supporting problem solving and
reinforcing existing coping strategies [26
&
,32].
Without the need for neoadjuvant chemother-
apy there is only a short window of opportunity
to improve John’s pulmonary function and fitness
prior to surgery [33,34], so the focus should shift
towards enhanced recovery after surgery. Early
mobilization is an important aspect of postoperative
care, to be encouraged by all the team. There
is limited evidence on which protocol to adopt
[35
&
], but the patient who can mobilize quickly
becomes an active participant in their care [36]. This
might again reduce postoperative complications
and risk of prolonged stay or readmission. John
is a good candidate for pulmonary rehabilitation,
which can reduce symptom burden and enhance
exercise capacity following lung resection [37,38].
From the first contact this plan can be introduced,
along with counselling to find new activities in the
recovery phase. Patients often adopt sedentary
behaviours despite successful primary treatment
of disease, but something as simple as a step
counter/pedometer may help them to self-manage
this [39,40].
CASE #2: COMMENCED RADICAL
CHEMORADIOTHERAPY
Doris, aged 65, has COPD and presented with cough
and weight loss (Fig. 2). She was diagnosed with
a radically treatable T1aN2Mo squamous cell
carcinoma of the lung. She commenced radical
chemo-radiation therapy but following cycle 1 of
chemotherapy was admitted with acute sepsis. Her
weight at diagnosis had dropped 13kg since docu-
mented 2 years previously, and has since dropped
a further 6 kg despite enteral support. Doris had a
current BMI of 14.7 kg/m2 and performance status
of 2. Her appetite remains poor and she has a high
CRP of 280mg/L. She is a retired landlady, is wid-
owed with no children, and currently lives alone but
has supportive neighbours. Her admission might
prompt a change inmedical management including
stopping her chemotherapy and altering the dose
per fraction of radiotherapy. Prophylactic septrin
could help avoid opportunistic chest infections
while her radiotherapy continues and nutritional
support with pabrinex and vitamin B12 could
be offered.
This patient has severe malnutrition despite
enteral support. The persistent inflammatory
response, possibly fuelled by recurrent infection,
has contributed to her ongoing weight loss and
treatment may have further reduced appetite and
food intake. A full review of symptoms is warranted.
Ideally this would have occurred prior to her starting
treatment to improve tolerance to it. The use of n-3
polyunsaturated fatty acids in addition to protein
and energy dense nutritional supplementsmay have
helped support performance status and quality of
life [41]. A self-management approach to eating can
help retain a sense of control [42,43]. Doris could be
advised to eat and drink at times when her cough
is least problematic and use nutrition dense snacks
and fluids, for example, milk drinks of fortified
soups, to increase intake in spite of symptoms.
Appetite stimulantsmay have a role. On completion
of radiotherapy proactive monitoring and manage-
ment of oesophagitis is required to ensure this does
not further exacerbate the poor intake. Enteral tube
feeding may be required in circumstances if oral
intake is particularly compromised and nutritional
status deteriorating. Treatment-related anaemia,
pneumonitis and physical inactivity might have
reduced Doris’ exercise tolerance, particularly
during her recent hospital admission [3,44]. Studies
Doris:
Commenced
radical
chemoradio-
therapy
Prophylactic
septrin to avoid
opportunistic
chest infections
Review oral
intake and
consider appetite
stimulants
Advise to eat at
times when
cough is least
problematic
Consider n-3
polyunsaturated
fatty acids and
oral nutritional
supplements
Promote walking
as a social
opportunity to
exercise
Encourage
uptake of
pulmonary
rehabilitation
Explore how
neighbours may
be willing and
able to help
FIGURE 2. Doris, commenced radical chemoradiotherapy.
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support exercise alongside chemoradiotherapy
therapy [45
&&
]. Although no study has purposefully
selected cachectic patients [46], exercise has an anti-
inflammatory effect [47] and can help maintain
function. If local rehabilitation services are available
a referral should be discussed. With her concurrent
COPD diagnosis Doris would be an excellent candi-
date for pulmonary rehabilitation [48,49] despite
her current frailty [50
&
,51]. Doris should be encour-
aged to stay as active as she feels able [52,53],
perhaps to start walking with friends or neighbours
on a few days of each week as a social activity [54].
CASE #3: RECEIVING PALLIATIVE
CHEMOTHERAPY
Nancy, aged 71, was recently diagnosed with stage
IV squamous cell lung carcinoma having presented
to her GP with breathlessness (Fig. 3). She had
a pleural effusion which was drained, and has a
medical history of a cardiac pacemaker, small hiatus
hernia, and hypercholesteraemia. She lives with her
husband and has four grown children nearby. Her
performance status is 1 and she mobilizes with a
walking stick,mainly for confidence. Nancy’s BMI at
diagnosis was 28.5 kg/m2. She had lost 5 kg but this
did not cause her particular concern as she had been
keen to lose weight. Her appetite remains low and
her breathlessness persists. She was prescribed pal-
liative chemotherapy with gemcitabine/carboplatin
and baseline bloods revealed an ESR of 116mm/h
and CRP of 58mg/L. Her oncological management
included prescribing postchemotherapy supportive
medications (antiemetics, proton pump inhibitors
and steroids), treating constipation, and close
monitoring of tolerance to chemotherapy.
Breathlessness and poor appetite here will have
had a significant impact on the dietary intake for
this patient leading to malnutrition. Malnourished
patients have a poorer outcome compared with
those who are not malnourished at diagnosis [55]
so symptom control is a priority. Given Nancy’s age
and comorbidities, polypharmacy may be contribu-
ting to her symptoms and a geriatric assessment is
worthwhile. Achieving sufficient dietary intake can
be difficult in the older breathless patient, who often
reduce the frequency of eating and have dietary
profiles with little variety and unusually high
proportions of liquids [56]. Consideration should
be given to foods and fluids that maximize dietary
intake but are easy to eat and drink, for example,
foods that are soft and can be fortified. Oral nutri-
tional supplements may be an option if found
suitably palatable. The home support from her hus-
band and grown children is important. Families can
support or challenge the patient’s approach to pro-
gressing disease and changing eating habits [57,58]
and should be closely involved in management
where possible. It can be important to support the
patient’s plans to tell family about best and worst
case scenario from treatment and negotiate with
their family. There is also a role in preparing the
family in the case of rapidly progressing disease
where they may engage in futile attempts to feed
that cause distress [43]. Acknowledging the import-
ance of meals for maintaining relationships can be
useful, as can suggesting ways Nancy can continue
to be part of daily family routines and events
without feeling pressure to eat, such as offering ‘help
yourself’ meals.
Nancy’s favourable performance status should
assist her getting through her palliative chemother-
apy, indeed performance status, functional capacity
and activity behaviours are all predictors of overall
survival [59]. Physical activity level should be seen as
a ‘vital sign’ reflecting current wellbeing. Whilst
whenNancy feels in need of rest this should happen,
she should be permitted and encouraged to con-
tinue usual activity behaviours such as the house-
work, gardening and hobbies. With her symptoms,
advice should be offered on activity planning and
pacing ‘balancing activity and rest’ and ‘listening
to your body’, along with simple way to manage
breathlessness, such as using a handheld fan or
cooledwater spray. ReassuringNancy andher family
about normal exertional responses to activity can
also be helpful [60]. They could be directed towards
web-based information and guidance to support
active living, for example, from Macmillan Cancer
Care. Although formal exercise services are not often
Nancy:
Started
palliative
chemotherapy
Supportive
medicines, e.g.
anti-emetics,
steroids
Carefully
monitor
chemotherapy
tolerance
Advise on soft,
easy to eat,
fortified foods
Provide tools
to manage
shortness of
breath, e.g.
hand held fan
Support family
discussion on
best and worse
case treatment
outcomes
License usual
physical
activity, e.g.
housework,
gardening
Offer simple
home exercises
e.g. step ups,
sit to stand
FIGURE 3. Nancy, receiving palliative chemotherapy.
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available, many patients report a readiness to
take up light self-managed exercise during chemo-
therapy [61,62]. Simple home exercises that do not
require equipment can be taught, for example step-
ups and sit-to-stands with a focus on a slow and
controlled movement. Furthermore palliative care
services, including hospices, may provide rehabili-
tation services that the patient may be willing to
explore [63–65].
CASE #4: NO PLANNED ANTI-CANCER
THERAPY
Marc, aged 63, was diagnosed with a Stage IV mixed
large cell/neuroendocrine lung tumour following
flu-like symptoms that restricted his work as a
carpenter (Fig. 4). His performance status had deter-
iorated rapidly in the last month, fromWHO 1 to 3,
and he reported significant weight loss. Additional
symptoms included chronic fatigue, cough, consti-
pation, peripheral oedema. Marc’s BMI was 19.3 kg/
m2 and blood tests revealed a high CRP of 232mg/L.
His planned management was for best supportive
care. The oncologist assessed Marc for palliative
radiotherapy to improve his cough, prescribed oral
laxatives for his constipation as a nutritional impact
symptom, diuretics to improve peripheral oedema,
and a short-course of corticosteroids to stimulate
appetite and alleviate fatigue. Timely involvement
of palliative care was also prioritized.
Marc’s nutritional markers (weight loss, poor
appetite and increased CRP) suggest refractory
cachexia [1] and with such rapid deterioration the
provision of nutrition is unlikely to prevent further
change in body composition. The deterioration in
performance status and loss of body weight is likely
to cause concern and distress to Marc and his family
[21]. Therapeutic discussion should cover the causes
of weight loss, main symptoms and what changing
dietary intake can and cannot realistically achieve.
Regarding nutrition, the focus might be to eat for
pleasure whilst maintaining an adequate fluid
intake – finding foods and fluids that provide best
taste, are easy to eat, and taking small portion sizes.
The link between constipation and drinking plenty
of fluids could also be made. The use of oral nutri-
tional supplements is unlikely to provide clinical
benefit so these should only be considered if they are
liked by the patient and requested. It can be helpful
to include those preparing food in the discussion,
often the family, to ensure their role is supportive.
A clear explanation of what causes weight loss, for
example, there may be a malnutrition component,
but it is likely predominantly caused by disease and
not anyone’s fault, may help to alleviate the anxiety
around appetite and eating, and help manage
expectations [66]. The reduced performance status
will also threatenMarc’s physical independence and
normal ‘role’, particularly with regard to his work
[23
&
,67]. An intense exercise programme targeting
change in body composition is unlikely to be
realistic or helpful. Instead the focus should be
on maintaining independence in activities of daily
living, involving the family who will be at home
supporting Marc. The provision of a mobility aid
and/or assistive equipment should be considered, to
promote impendence in and around the home
[55,68]. It is common for family members to be
uncertain what to do, so a supportive approach
that encourages the patient to talk about their pref-
erences and how best to manage change can be
useful [69], for example asking: ‘how would you
prefer them to help?’. Family members sometimes
default to doing everything for their loved one in an
attempt to preserve their energy levels, including
tasks they are capable of doing independently.
A reminder that independence is often important
to people may help family members to offer care
that enables rather than limits daily activity.
IMPLEMENTING MULTIMODAL CARE IN
PRACTICE
These cases highlight numerous component treat-
ments to consider, and provide three key messages
to support multimodal care for cancer cachexia in
practice. First, everymember of the clinical team can
contribute towards multimodal care. Multimodal
care includes addressing nutritional impact symp-
toms, for example, sore mouth, constipation, pain,
which interfere with intake and absorption and
Marc:
No planned
anti-cancer
therapy
Focus on eating
for pleasure
and maintaining
fluid intake
Consider short-
term steroids to
improve
appetite and
fatigue
Oral laxatives
to reduce
constipation
Explore
mobility aids
and assistive
equipment
Assess ability to
perform
everyday tasks
with family
Elicit patient
preferences
around family
support
Educate spouse
about eating-
related distress
FIGURE 4. Marc, no planned anticancer therapy.
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compound cachexia. Assessing and managing these
symptoms is an important part of multimodal care
within reach of all clinicians. A holistic needs assess-
ment can uncover additional patient and family
needs relating to cachexia and prompt appropriate
education and management. It is not always
possible to refer to specialists, or there can be long
wait lists, so simple practical advice should become
part of each team member’s repertoire. This would
be supported by a commitment to inter-professional
learning and working. Second, multimodal care for
cancer cachexia should be person centred and focus
on supported self-management. Treatments to
improve or maintain physical, psychological and
social functioning often require behaviour change
and should be tailored to individual and the sur-
rounding context. The patient’s family and social
support network are often important, and including
them in the promotion and monitoring of health
behaviours, for example, preparing meals or being
physically active, can be invaluable. In line with this
patient reported outcomes also have a role in rec-
ognizing successful care [70]. Third, multimodal
approaches can ask a lot of the patient and their
family. When introducing new treatments it is help-
ful to remind patients that they are buying-in to an
approach to care, rather than signing up to a strict,
often challenging treatment regimen. Adherence is
key, so new requests or treatments should always be
considered and introduced in line with the
whole approach.
Once multimodal care is operationalized it can
then be tested pragmatically, either alone or along-
side pharmacological treatments. Some centres have
developed cachexia clinics and offer working
models to build an evidence base for multimodal
care. Emerging trials also show promise for pharma-
cological agents, for example, ghrelin receptor ago-
nists, myostatin, SARMs [19,71
&&
]. There may soon
be new therapies to prescribe for cancer cachexia,
but arguably these should be offered on a back-
ground of good multimodal care [23
&
,71
&&
]. To test
this argument trials may be needed to monitor the
combined effects of exercise and nutrition, and anti-
inflammatory medicines, with or without cachexia
drug therapies [20]. Such designs have increasing
importance given the regulatory perspective on
functional trial endpoints [19,72].
CONCLUSION
This case-based paper highlights practical ways to
provide multimodal care for cancer cachexia. Across
a rangeof clinical scenarios, wedemonstrate that this
can be achieved with simple treatments and without
a dedicated team of specialists. As multimodal care is
part of everyone’s remit, the sharing of advice and
experiences between health professionals can help
build confidence and expertise, moving towards a
position where every team member feels they can
contribute towards cachexia care.
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